Reducing unwanted emulsion polymerization during extractive distillation of conjugated diene monomers
By using composition inhibitors that stabilize nitrogen oxygen radicals and phenylenediamine in the extraction and distillation process of ethylenically unsaturated monomers, the problem of premature polymerization of ethylenically unsaturated monomers is solved, and the problem of premature polymerization of ethylenically unsaturated monomers is prevented. Equipment scaling and product pollution improve production efficiency.
Patent Information
- Application Number
- CN202380031718.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-01
- Filing Date
- 2023-03-28
- Publication Date
- 2024-11-22
AI Technical Summary
Ethylene unsaturated monomers are prone to premature polymerization at high temperatures, resulting in equipment scaling and product contamination. The existing polymerization inhibitors are insufficiently distributed in the non-polar monomer layer, which cannot effectively prevent emulsion polymerization.
Using a composition comprising a first inhibitor compound that stabilizes nitrogen oxygen radicals and a second inhibitor compound of phenylenediamine, the composition is added to inhibit monomer polymerization by the addition of the composition in the extraction distillation process, utilizing it in polarity and non- Distribution properties in polar solvents prevent emulsion polymerization.
It significantly reduces the premature polymerization of ethylenically unsaturated monomers, prevents equipment scaling and product contamination, improves production efficiency and reduces economic losses from operational downtime.
Smart Images

Figure CN119013243A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure generally relates to compositions including blends of polymerization inhibitors and methods of using the same. More specifically, the present disclosure relates to compositions including at least one compound having a stable nitroxide radical and a phenylenediamine that can be used to inhibit emulsion polymerization of ethylenically unsaturated monomers. Background Art
[0002] The manufacture of ethylenically unsaturated monomers generally includes three stages: reaction, crude product recovery and product purification by fractionation. Distillation operations performed at high temperatures generally involve recovery and purification stages. Ethylenically unsaturated monomers (such as styrene, butadiene, isoprene, divinylbenzene, cyclopentadiene, dicyclopentadiene, vinyl acetate, acrylate and methacrylate monomers) are present in crude process streams or in refined products prepared by various chemical industrial processes. However, the monomers are highly reactive, particularly at high temperatures, in the presence of oxygen or when in contact with metal oxide surfaces. Therefore, these monomer types are very susceptible to undesirable polymerization by free radical polymerization. This problem is serious, particularly at high temperatures and in the presence of polymerization initiators (such as organic peroxides). The resulting polymer may be problematic and lead to equipment "fouling" and product contamination and consumption. Once the resulting polymer is precipitated from the solution during the processing stage and deposited on the equipment surface, production efficiency is reduced. As a result of fouling of process equipment, operations must be stopped to mechanically clean the equipment and / or remove undesirable polymers. Operational interruptions result in substantial economic losses for operators. The polymer may also remain in solution as a soluble product contaminant. Contamination may require additional processing steps to remove the contaminant polymer from the final product composition stream or stored product. All of the above problems necessitate the development and use of on-line chemical cleaning programs to mitigate fouling and thereby eliminate economically expensive operational downtime.
[0003] Premature polymerization of these monomers is usually mitigated by metering in polymerization inhibitors which are capable of eliminating or significantly reducing premature polymerization of the monomers. Conventional polymerization inhibitors include stable free radicals which are effective in scavenging carbon-centered free radicals.
[0004] During the extractive distillation of reactive conjugated diene monomers such as butadiene and isoprene, the low polar monomers are suspended in a bulk phase and a high polar solvent such as N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), and acetonitrile. Unless effective inhibitors are used, the dispersed monomers undergo unwanted free radical polymerization. This results in fouling, which can lead to production losses and unexpected downtime.
[0005] Conventional polymerization inhibitors, such as 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (HTEMPO) and 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl (OTEMPO), are substantially distributed in the bulk phase and to a lesser extent in the non-polar droplets of reactive monomers, which makes them ineffective in preventing emulsion polymerization. Summary of the invention
[0006] A composition for inhibiting monomer polymerization is provided, which comprises a first inhibitor compound containing a stable nitroxide free radical and a second inhibitor compound including phenylenediamine.
[0007] In some aspects, the first inhibitor compound has Formula (I):
[0008]
[0009] Where R1 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
[0010] In some aspects, the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1-ol 4-Heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Octyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Decyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Tridecyloxy-2,2,6,6-tetramethylpiperidin -1-oxy; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-decyloxy-2,2,6,6- tetramethylpiperidin-1-oxy; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-oxy; and any combination thereof.
[0011] In some aspects, the first inhibitor is a compound of Formula III:
[0012]
[0013] wherein R3 is -O· or -OH; and R4 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
[0014] In some aspects, the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate; and any combination thereof.
[0015] In some aspects, the second inhibitor compound is a phenylenediamine of Formula (IV) or Formula (V):
[0016]
[0017] Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
[0018] In some aspects, X1 and X2 are independently C1-C 22 Alkyl or phenyl, wherein the alkyl and phenyl are optionally replaced by one or more C1-C 22 Alkyl or aryl substituted.
[0019] In some aspects, X1 and X2 are independently C1-C 10 Alkyl or phenyl, wherein the alkyl and phenyl are optionally replaced by one or more C1-C 22 Alkyl or aryl substituted.
[0020] In some aspects, X1 and X2 are independently C1-C5 alkyl or phenyl, wherein the alkyl and phenyl are optionally substituted with one or more C1-C5 alkyl groups. 22 Alkyl or aryl substituted.
[0021] In some aspects, the second inhibitor is selected from the group consisting of: 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, N,N′-diphenyl-1,4-phenylenediamine, and any combination thereof.
[0022] In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 80 wt %.
[0023] In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01 wt % to about 50 wt %.
[0024] In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:100.
[0025] In some aspects, the composition further comprises an organic solvent.
[0026] In some aspects, the composition further comprises an ethylenically unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid, and any combination thereof.
[0027] A method for inhibiting polymerization of monomers is provided. The method comprises adding a composition to a process stream in an extractive distillation process. The composition comprises a first inhibitor compound comprising a stable nitroxide free radical; and a second inhibitor compound comprising phenylenediamine. The process stream comprises micelles.
[0028] In some aspects, the process stream includes a monomer.
[0029] In some aspects, the process stream includes a solvent selected from DMF (N,N-dimethylformamide) / furfural, NMP (N-methylpyrrolidone), acetonitrile, and mixtures thereof. Sometimes, stratification or micelles occur during the extractive distillation process. Two immiscible layers are formed: a non-polar monomer layer and a polar solvent layer.
[0030] In some aspects, the ethylenically unsaturated monomer partitions to a greater extent into one of the at least one non-polar extractive distillation solvents than into the at least one polar extractive distillation solvent.
[0031] In some aspects, the inhibitor formulation has the ability to partition from the polar solvent layer to the monomer layer to inhibit premature emulsion polymerization in both layers.
[0032] In some aspects, the process stream further comprises at least one polar extractive distillation solvent and at least one non-polar extractive distillation solvent comprising at least one ethylenically unsaturated monomer.
[0033] In some aspects, the at least one polar extractive distillation solvent and the at least one non-polar extractive distillation solvent are immiscible with each other.
[0034] In some aspects, the first inhibitor or the second inhibitor partitions to a greater extent into the at least one non-polar extractive distillation solvent than into the at least one polar extractive distillation solvent.
[0035] In some aspects, the at least one non-polar extractive distillation solvent is furfural, tetrahydrofuran, pentane, hexane, heptane, octane, nonane, decane, undecane, dodecane, tridecane, tetradecane, benzene, toluene, ethylbenzene, ethyltoluene, methylene chloride, tetrachloromethane, pentene, hexene, heptene, octene, nonene, decene, undecene, dodecene, tridecene, tetradecene, cyclopentane, cyclopentene, cyclohexane, cyclohexene, dicyclopentane, cyclopentadiene, dicyclopentadiene, ethyl acetate, ethyl propionate, ethyl butyrate, ethyl valerate, ethyl Esters, ethyl caproate, ethyl heptanoate, ethyl nonanoate, ethyl decanoate, ethyl undecanoate, ethyl dodecanoate, ethyl tridecanoate, ethyl tetradecanoate, ethyl pentadecanoate, ethyl hexadecanoate, ethyl octadecanoate, ethyl behenate, methyl acetate, methyl propionate, methyl butyrate, methyl valerate, methyl caproate, methyl heptanoate, methyl nonanoate, methyl decanoate, methyl undecanoate, methyl dodecanoate, methyl tridecanoate, methyl tetradecanoate, methyl pentadecanoate, methyl hexadecanoate, methyl octadecanoate, methyl behenate, propyl acetate, propyl propionate, propyl butyrate, Propyl valerate, propyl hexanoate, propyl heptanoate, propyl nonanoate, propyl decanoate, propyl undecanoate, propyl dodecanoate, propyl tridecanoate, propyl tetradecanoate, propyl pentadecanoate, propyl hexadecanoate, propyl octadecanoate, propyl behenate, butyl acetate, butyl propionate, butyl butyrate, butyl valerate, butyl hexanoate, butyl heptanoate, butyl nonanoate, butyl decanoate, butyl undecanoate, butyl dodecanoate, butyl tridecanoate, butyl tetradecanoate, butyl pentadecanoate, butyl hexadecanoate, butyl octadecanoate, butyl behenate, hexyl acetate, hexyl propionate, butyrate octanoate, octyl propionate, octyl butyrate, octyl valerate, octyl hexanoate, octyl heptanoate, octyl nonanoate, octyl decanoate, octyl undecanoate, octyl dodecanoate, octyl tridecanoate, octyl tetradecanoate, octyl pentadecanoate, octyl hexadecanoate, octyl octadecanoate, octyl behenate, octyl acetate, octyl propionate, octyl butyrate, octyl valerate, octyl hexanoate, octyl heptanoate, octyl nonanoate, octyl decanoate, octyl undecanoate, octyl dodecanoate, octyl tridecanoate, octyl tetradecanoate, octyl pentadecanoate, octyl hexadecanoate, octyl octadecanoate, octyl behenate, and any combination thereof.
[0036] In some aspects, the at least one non-polar extractive distillation solvent is an alkane, an alkene, a cycloalkane, a cycloalkene, an aryl, an alkylaryl, an arylalkyl, an organic ester, an ether, a cyclic ether, and / or other non-polar solvents known in the art.
[0037] In some aspects, the at least one non-polar extractive distillation solvent is selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, and any combination thereof.
[0038] In some aspects, the at least one polar extractive distillation solvent is selected from N,N-dimethylformamide, furfural, N-methylpyrrolidone, acetonitrile, water, and combinations thereof.
[0039] In some aspects, the monomer is an ethylenically unsaturated monomer.
[0040] In some aspects, the composition is added to the process stream such that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm.
[0041] In some aspects, the composition is added to the process stream such that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm.
[0042] In some aspects, the monomer is selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, divinylbenzene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, and any combination thereof.
[0043] The above has been a fairly extensive overview of the features and technical advantages of the present disclosure so that the following specific description may be better understood. Other features and advantages of the present disclosure will be described below, which constitute the subject matter of the claims of this application. It will be appreciated by those skilled in the art that the disclosed concepts and specific aspects may be readily used as a basis for modifying or designing other aspects for achieving the same purpose of the present disclosure. It will also be appreciated by those skilled in the art that such disclosure of equivalent aspects does not depart from the spirit and scope of the present disclosure as described in the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Specific embodiments of the present invention are described below in detail with reference to the accompanying drawings.
[0045] Figure 1 Shown isoprene polymerization in DMF at 95 °C.
[0046] Figure 2 Shown isoprene polymerization in heptane at 95 °C. DETAILED DESCRIPTION
[0047] Various aspects of the present disclosure are described below. The relationship and function of various aspects of the elements can be better understood by reference to the following detailed description. However, various aspects are not limited to those explicitly described herein, and it should be understood that in some cases, details that are unnecessary for understanding various aspects disclosed herein, such as, for example, conventional synthesis and / or preparation, may have been omitted.
[0048] During extractive distillation of reactive conjugated diene monomers, emulsion polymerization may occur, resulting in unwanted fouling. A polymerization inhibitor that can effectively prevent emulsion polymerization is needed. The compositions and methods disclosed herein can prevent or reduce emulsion polymerization.
[0049] A method for inhibiting monomer polymerization is provided. The method comprises adding a composition to a process stream in an extractive distillation process. The composition comprises a first inhibitor compound comprising a stable nitroxide free radical and a second inhibitor compound comprising a phenylenediamine. The process stream comprises micelles.
[0050] As used herein, "micelle" refers to an aggregate of amphiphilic molecules. Micelles are formed when unequal amounts of two immiscible liquids are stirred so that a small amount of liquid is dispersed as droplets in a larger amount of liquid. The dispersed droplets constitute the micelles, while the bulk liquid is the continuous phase.
[0051] The present disclosure relates to compositions including blends of polymerization inhibitors and methods of using the same to inhibit polymerization of ethylenically unsaturated monomers. The polymerization inhibitor compositions of the present disclosure include at least one compound having thermally and chemically stable nitroxide free radicals and phenylenediamine. The polymerization inhibitor composition may be a blend of multiple components, including components other than the above-mentioned compounds having stable nitroxide free radicals and phenylenediamine.
[0052] In the presence of polymerizable monomers, a "polymerization inhibitor" inhibits the polymerization of these monomers during the induction time under shutdown conditions. After the induction time has elapsed after the polymerization inhibitor is completely consumed, polymer formation occurs at the same rate as in the complete absence of the polymerization inhibitor.
[0053] Polymerization inhibitors and polymerization retarders are generally considered "anti-polymerization agents," which are compounds that can inhibit or reduce the formation of polymers from one or more free radically polymerizable compounds.
[0054] The term "fouling" refers to the formation of polymers, prepolymers, oligomers and / or other materials that are insoluble in the stream and / or precipitate out of the stream and deposit on the equipment under the operating conditions of the equipment. In turn, the inhibitor compositions of the present disclosure may be referred to as "antifouling" because they inhibit or reduce the formation of fouling polymers.
[0055] Compositions of the present disclosure
[0056] The present disclosure relates to a composition for inhibiting the polymerization of monomers, wherein the composition comprises a first inhibitor compound having a stable nitroxide free radical and a second inhibitor compound, phenylenediamine. In some aspects, the composition used herein is particularly useful under high severity conditions in a distillation column. In some aspects, the composition is used to inhibit the polymerization of monomers, wherein the monomer is an ethylenically unsaturated monomer. For example, the composition of the present disclosure can be used to inhibit the polymerization of ethylenically unsaturated monomers, and the ethylenically unsaturated monomers include, but are not limited to, vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, acrylic acid, (meth) acrylic acid, and combinations thereof.
[0057] In some aspects, the compositions of the present disclosure can be used to inhibit the polymerization of ethylenically unsaturated monomers under high severity operating conditions.
[0058] In some aspects, the first inhibitor compound having a stable nitroxide radical is a compound of formula (I):
[0059]
[0060] Where R1 is H, C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl, C1-C 22 Cycloalkyl, aryl, -C1-C 22 Alkylene aryl, -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C1-C 22 alkylene aryl), wherein the alkyl, cycloalkyl and aryl are optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.
[0061] The term "aryl" refers to monocyclic, bicyclic (fused) and tricyclic (fused or spiro) hydrocarbon ring systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring carbon atoms. The term "aryl" can be used interchangeably with the term "aryl ring".
[0062] In certain aspects, R1 is -C(O)(C1-C 22 Alkyl), -C(O)(C1-C22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) or -C(O)(C1-C 22 alkylene aryl), wherein the alkyl, cycloalkyl and aryl are optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl and aryl substitution.
[0063] In some aspects, R1 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
[0064] In some aspects, R1 is H. In some aspects, R1 is C1-C 22 In some aspects, R1 is C1-C 22 In some aspects, R1 is C1-C 22 In some aspects, R1 is C1-C 22 Cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is aryl, wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is -C1-C 22 Alkylene aryl, wherein the aryl group is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is -C(O)(C1-C 22 In some aspects, R1 is -C(O)(C1-C 12 In some aspects, R1 is -C(O)(C1-C6 alkyl). In some aspects, R1 is -C(O)(methyl). In some aspects, R1 is -C(O)(ethyl). In some aspects, R1 is -C(O)(propyl). In some aspects, R1 is -C(O)(butyl). In some aspects, R1 is -C(O)(C1-C6 alkyl). 22 In some aspects, R1 is -C(O)(C1-C 22 In some aspects, R1 is -C(O)(C1-C22 cycloalkyl), wherein the cycloalkyl is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is -C(O)(aryl), wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R1 is -C(O)(C1-C 22 alkylene aryl), wherein the aryl group is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.
[0065] Examples of compounds of formula (I) include, but are not limited to, 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-hexyloxy-2,2,6,6-tetramethylpiperidin- 1-oxy; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-tridecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-decyloxy-2,2, 6,6-tetramethylpiperidin-1-oxy; 4-diicosanyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-diicosanyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-diicosanyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-docosanyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxy; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxy; or 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-oxy.
[0066] In other aspects, the first inhibitor compound has formula (II):
[0067]
[0068] Wherein R2 is selected from H, C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl, C1-C 22 Cycloalkyl, aryl, -C1-C 22 Alkylene, -C(O)(C1-C 22Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) and -C(O)(C1-C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.
[0069] In certain aspects, R2 is -C(O)(C1-C 22 Alkyl), -C(O)(C1-C 22 alkenyl), -C(O)(C1-C 22 Alkynyl), -C(O)(C1-C 22 Cycloalkyl), -C(O)(aryl) and -C(O)(C1-C 22 alkylene), wherein the alkyl, alkylene, cycloalkyl and aryl groups are optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.
[0070] In some aspects, R2 is H. In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 In some aspects, R2 is C1-C 22 Cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is aryl, wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C1-C 22 Alkylene, wherein the alkylene is optionally substituted by aryl, the aryl is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(C1-C 22 In some aspects, R2 is -C(O)(C1-C 12In some aspects, R2 is -C(O)(C1-C6 alkyl). In some aspects, R2 is -C(O)(methyl). In some aspects, R2 is -C(O)(ethyl). In some aspects, R2 is -C(O)(propyl). In some aspects, R2 is -C(O)(butyl). In some aspects, R2 is -C(O)(C1-C6 alkyl). 22 In some aspects, R2 is -C(O)(C1-C 22 In some aspects, R2 is -C(O)(C1-C 22 cycloalkyl), wherein the cycloalkyl is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(aryl), wherein the aryl is optionally substituted with one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 In some aspects, R2 is -C(O)(C1-C 22 alkylene), wherein the alkylene is optionally substituted by an aryl group, the aryl group is optionally substituted by one or more C1-C 22 Alkyl, C1-C 22 Alkenyl, C1-C 22 Alkynyl or aryl substitution.
[0071] In some aspects, the compound of formula (II) is 2,2,6,6-tetramethylpiperidin-1,4-diol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1 -ol; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-tridecyloxy-2,2,6,6-tetramethylpiperidin -1-ol; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6 ,6-tetramethylpiperidin-1-ol; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-ol; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-ol; or 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-ol.
[0072] In some aspects, the compositions of the present disclosure comprise compounds of formula (I) and (II), respectively, wherein R1 and R2 are the same. For example, in some aspects, the compositions of the present disclosure comprise compounds of formula (I) and (II), respectively, wherein R1 and R2 are each independently -C(O)(C1-C 22 In certain aspects, the compositions of the present disclosure comprise a first inhibitor compound and a second inhibitor compound of formula (I) and (II), respectively, wherein R1 and R2 are different.
[0073] The compounds of formula (II) with hydroxylamine disclosed in the present invention have advantages over the corresponding nitrogen oxides (compounds of formula (I)), such as the ability to provide additional polymerization inhibition, which will be explained more fully below. The general synthetic route of hydroxylamine to produce nitrogen oxides is to reduce its corresponding nitrogen oxide with a reducing agent as follows:
[0074]
[0075] Hydroxylamines of nitroxides have the potential to provide additional polymerization inhibition compared to the corresponding nitroxides in the presence of carbon-centered and oxygen-centered free radical initiators. This is explained as follows:
[0076]
[0077] Due to its weak NO-H bond in the compound, the hydroxylamine of nitrogen oxide is an excellent hydrogen donor, so it is an effective antioxidant. As an antioxidant, the hydroxylamine of nitroxide free radical easily reacts with oxygen-centered free radicals (such as peroxide free radicals), and it is converted into its corresponding nitroxide free radical. Nitrogen oxides are generally considered to be the most effective inhibitors because they have excellent inhibition ability by removing carbon-centered free radicals at a rate that almost controls diffusion. This rate is several orders of magnitude faster than phenolic compounds. However, their kinetic superiority is not always favorable. For example, when oxygen-centered free radicals exist as the main free radicals, it may lose its superiority. Another problem related to nitrogen oxides is its consumption by non-inhibition and undesirable reactions with process stream components or other inhibitor additives. Therefore, high nitrogen oxide inhibitor dosages are usually required for a given inhibition efficacy, making their use economically unattractive or even unfeasible.
[0078] In essence, when both oxygen-centered free radicals and carbon-centered free radicals are present, each hydroxylamine of the nitroxide is equivalent to a hydrogen donor plus a nitroxide anti-polymerizer, which is an attractive motivation provided by the hydroxylamine of the nitroxide. That is, one hydroxylamine of the nitroxide can eliminate one oxygen-centered free radical and one carbon-centered free radical, while the nitroxide can only eliminate the carbon-centered free radical.
[0079] In some aspects, the first inhibitor is a compound of Formula III:
[0080]
[0081] wherein R3 is -O· or -OH; and R4 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
[0082] In some aspects, R3 is -O. In some aspects, R3 is -OH.
[0083] In some aspects, R4 is optionally replaced by one or more C1-C 22 Alkyl or aryl substituted C1-C 22 In some aspects, R4 is optionally replaced by one or more C1-C 22 Alkyl or aryl substituted aryl.
[0084] Examples of compounds of formula (iii) include, but are not limited to, 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 6-tetramethylpiperidin-4-yl ester; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; or 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate.
[0085] In some aspects, the second inhibitor compound is a phenylenediamine of Formula (IV) or Formula (V):
[0086]
[0087] Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
[0088] In some aspects, the second inhibitor compound is a phenylenediamine of formula (IV). In some aspects, the second inhibitor compound is a phenylenediamine of formula (V).
[0089] Examples of phenylenediamines include, but are not limited to, 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, and N,N′-diphenyl-1,4-phenylenediamine.
[0090] In some aspects, the composition comprises 2,2',6,6'-tetramethylpiperidinyl-1-oxyl and an alkyl-substituted 1,4-phenylenediamine.
[0091] In some aspects, the composition consists essentially of the first inhibitor compound and the second inhibitor compound. In other aspects, the composition consists of an organic solvent, a first inhibitor, and a second inhibitor.
[0092] In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 80% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 70% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 60% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 40% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 30% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 20% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 10% by weight.
[0093] For example, in some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, about 50 wt %, about 55 wt %, about 60 wt %, about 65 wt %, about 70 wt %, about 75 wt %, or about 80 wt %.
[0094] In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 50% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 40% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 30% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 20% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% to about 10% by weight.
[0095] For example, in some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01 wt %, about 0.1 wt %, about 1 wt %, about 5 wt %, about 10 wt %, about 15 wt %, about 20 wt %, about 25 wt %, about 30 wt %, about 35 wt %, about 40 wt %, about 45 wt %, or about 50 wt %.
[0096] In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:100. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 90:1 to about 1:90. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 80:1 to about 1:80. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 70:1 to about 1:70. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 60:1 to about 1:60. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 50:1 to about 1:50. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 40:1 to about 1:40. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 30:1 to about 1:30. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 20:1 to about 1:20. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 10:1 to about 1: 10. In some aspects, the molar ratio of the first inhibitor compound to the second inhibitor compound is about 1:1.
[0097] In some aspects, the composition further comprises one or more additional compounds selected from the group consisting of: 2,2,6,6-tetramethylpiperidin-1-oxyl; 2,2,6,6-tetramethylpiperidin-1-ol; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-oxo-2 , 2,6,6-tetramethylpiperidin-1-ol; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol; and bis((2,2,6,6-tetramethylpiperidin-1-oxyl)-4-yl)oxalate. In some aspects, the composition further comprises 2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition further comprises 2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition further comprises 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition further comprises 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-propionyloxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes oxalic acid bis((2,2,6,6-tetramethylpiperidin-1-oxy)-4-yl) ester.
[0098] The composition can also optionally include one or more organic solvents. It will be appreciated by those of ordinary skill in the art that there are many organic solvents compatible with the composition of the present disclosure. For example, in some aspects, one or more organic solvents are selected from vinyl acetate, dimethyl phthalate, dimethyl formamide, toluene, xylene, high aromatic naphtha, acetonitrile, ethyl acetate, acetone, methylene chloride, tetrahydrofuran, hexane, dimethyl sulfoxide, N-methyl-2-pyrrolidone and combinations thereof. In some aspects, the composition also includes vinyl acetate. In some aspects, the composition also includes dimethyl phthalate. In some aspects, the composition also includes dimethyl formamide. In some aspects, the composition also includes toluene. In some aspects, the composition also includes xylene. In some aspects, the composition also includes high aromatic naphtha. In some aspects, the composition also includes acetonitrile.
[0099] In some aspects, the composition also includes one or more ethylenically unsaturated monomers. It will be appreciated by those of ordinary skill in the art that there are many ethylenically unsaturated monomers compatible with the compositions of the present disclosure. For example, in some aspects, one or more ethylenically unsaturated monomers are selected from vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, isoprene, (meth) acrylic acid and combinations thereof. In some aspects, the composition also includes vinyl acetate. In some aspects, the composition also includes acrylonitrile. In some aspects, the composition also includes acrylate. In some aspects, the composition also includes methacrylate. In some aspects, the composition also includes 1,3-butadiene. In some aspects, the composition also includes styrene. In some aspects, the composition also includes isoprene. In some aspects, the composition also includes (meth) acrylic acid.
[0100] In some aspects, the compositions disclosed herein do not include 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl. In some aspects, the compositions disclosed herein do not include 4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl. In some aspects, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl and 4-oxo-2,2,6,6-tetramethylpiperidine-1-oxyl are not added to ethylenically unsaturated monomers.
[0101] The present disclosure also relates to a method of inhibiting monomer polymerization, comprising adding a composition of the present disclosure to a monomer. In some aspects, an effective amount of a composition of the present disclosure is added to a monomer, wherein an effective amount is any amount sufficient to inhibit monomer polymerization. The process stream includes monomers and micelles.
[0102] In some aspects, the monomer is an ethylenically unsaturated monomer. In some aspects, the monomer is an ethylenically unsaturated monomer selected from the following items: vinyl acetate, acrylonitrile, acrylate, methacrylate, 1,3-butadiene, styrene, divinylbenzene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, (meth) acrylic acid and combinations thereof. In some aspects, the method disclosed herein can be used to inhibit the polymerization of vinyl acetate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylonitrile. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of methacrylate. In some aspects, the method disclosed herein can be used to inhibit the polymerization of 1,3-butadiene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of styrene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of isoprene. In some aspects, the method disclosed herein can be used to inhibit the polymerization of acrylic acid. In some aspects, the method disclosed herein can be used to inhibit the polymerization of (meth) acrylic acid.
[0103] The composition of the present disclosure can be added to the fluid manually or automatically. The composition can also be added continuously and / or intermittently. Automatic addition can be accomplished by using a chemical dosing pump. The chemical dosing pump can be programmed to add a specific amount of the polymerization inhibitor composition or any component thereof to the fluid at certain time intervals. In optional aspects, the chemical dosing pump can be manually controlled to add a specific amount of the polymerization inhibitor composition or any component thereof to the fluid. Adding the currently disclosed polymerization inhibitor composition to the monomer will thus inhibit the polymerization of the monomer.
[0104] In some aspects, the monomer is provided as a pure liquid. In other aspects, the monomer is provided in a solution, hereinafter referred to as a "monomer solution".
[0105] In some aspects, the monomer solution also includes one or more additional components selected from acid, organic solvent, water and combination thereof. For example, in some aspects, the monomer solution includes one or more organic solvents selected from the following items: vinyl acetate, dimethyl phthalate, dimethylformamide, toluene, ethyl toluene, xylene, high aromatic naphtha, acetonitrile, ethyl acetate, acetone, methylene chloride, tetrahydrofuran, hexane, dimethyl sulfoxide, N-methyl-2-pyrrolidone and combination thereof. In some aspects, the monomer solution includes one or more acids selected from hydrochloric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, boric acid, perchloric acid, formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, acetic acid, caprylic acid, undecanoic acid, lauric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid and suberic acid. In some aspects, the monomer solution includes water.
[0106] In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the first inhibitor compound is from about 0.1 ppm to about 500 ppm.
[0107] In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer so that the concentration of the second inhibitor compound is from about 0.1 ppm to about 500 ppm.
[0108] The method of the present disclosure can be used to inhibit premature polymerization of monomers during the extraction process. During the extraction process, a solvent is used to separate the components. The polarity difference between the extraction solvent and the hydrocarbon layer leads to emulsion formation, thereby increasing the risk of emulsion polymerization.
[0109] Examples of the extraction solvent include, but are not limited to, dimethylformamide (DMF), furfural, acetonitrile, N-methyl-2-pyrrolidone, and the like.
[0110] The methods of the present disclosure can also be used to prevent premature polymerization of styrene during the manufacturing and purification processes.
[0111] The method disclosed herein can also be used in butadiene extraction processes. This utility stems from the equilibrium partition coefficient between the polar organic phase and the non-polar organic phase.
[0112] In some aspects, the compositions disclosed herein are used for distillation purification of olefins. For example, the composition can be added to a process stream before entering a distillation unit, or the composition can be added to a process stream in a distillation unit.
[0113] Example
[0114] Example 1: Partition Coefficient
[0115] Tests were conducted to compare current industrially used chemistries (HTEMPO and OTEMPO) with the compositions of the present disclosure. The ester of HTEMPO 1 is 4-acetoxy-2,2'6,6'-tetramethylpiperidinyl-1-oxyl. The ester of HTEMPO 2 is 4-propionyl-2,2'6,6'-tetramethylpiperidinyl-1-oxyl. PDA is di-sec-butyl-4,4'-phenylenediamine.
[0116] Table 1 shows the partition coefficients for several tests between different solvent combinations.
[0117] Table 1
[0118]
[0119]
[0120] Polymerization Inhibitor (PI) The partition coefficient between toluene and water HTEMPO 18:82 Esters of HTEMPO 1 92:8 Esters of HTEMPO 2 97:3
[0121] Example 2: Isoprene polymerization test in DMF at 95°C
[0122] Commercial isoprene was passed through an alumina column to remove the stabilizer 4-tert-butylcatechol. A 100 mL wide-mouth bottle was charged with 0.2 g of an active polymerization inhibitor, 40 mL of heptane, 40 mL of DMF, and a stirring bar. The mixture was stirred at room temperature for 30 minutes and allowed to settle for 10 minutes.
[0123] DMF phase test: In a 100 mL wide-mouth bottle, 0.2 mL of the bottom layer of the previously settled two-layer mixture, 1 mL of azobisisobutyronitrile (AIBN) (0.0004 g / mL) solution, and 50 g of isoprene were placed. DMF was added to make the total weight of the solution 100 g. About 10 ml of the above mixture was added to 12 pressure tubes with a stirring rod and heated to 95°C. After 30 minutes and every 30 minutes thereafter, two tubes were removed from the block and the polymerization reaction was quenched by cooling in an ice bath. The cooled polymer solution was immediately diluted with toluene. The soluble polymer in the liquid was determined by turbidity.
[0124] Figure 1 It was shown that the compositions of the present disclosure significantly reduced isoprene polymerization compared to conventional polymerization inhibitors HTEMPO and OTEMPO. In addition, Figure 1 The combination of stable nitroxide radicals and phenylenediamines was shown to produce a synergistic effect.
[0125] exist Figure 1 and Figure 2%, "Prototype 1" is about 22 wt% 4-acetoxyTEMPO, about 5 to 8 wt% HTEMPO, HTEMPOH and hydroxylamine of 4-acetoxyTEMPO, and about 70% DMF, "Prototype 2" is "Prototype 1" plus PDA, "Commercial Product" is water containing 10% HTEMPO, and "PDA'" is as previously defined.
[0126] Example 3: Isoprene polymerization test in heptane at 95°C
[0127] Heptane phase: In a 100 mL wide-mouth bottle, 5.0 mL of the top layer of the previously settled two-layer mixture, 1 mL of AIBN (0.0004 g / mL) solution, and 50 g of isoprene were placed. Hexane was added to make the total weight of the solution 100 g. About 13 ml of the above mixture was added to 12 pressure tubes with a stirring bar and heated to 95°C. After 30 minutes and every 30 minutes thereafter, two tubes were removed from the block and the polymerization reaction was quenched by cooling in an ice bath. The cooled polymer solution was immediately diluted with toluene. The soluble polymer in the liquid was determined by turbidity. The results can be seen in Figure 2 Used to generate Figure 2 The data for the trend line in can be seen in Table 2.
[0128] Table 2: Figure 2 Polymerization growth data in heptane phase (in terms of polyisoprene w / w %)
[0129]
[0130] All compositions and methods disclosed and claimed herein can be prepared and performed according to the present disclosure without undue experimentation. Although the present invention can be embodied in many different forms, specific preferred embodiments of the present invention are described in detail herein. The present disclosure is an illustration of the principles of the present invention and is not intended to limit the present invention to the specific embodiments shown. In addition, unless explicitly stated to the contrary, the use of the term "a / an" is intended to include "at least one" or "one or more". For example, "inhibitor" is intended to include "at least one inhibitor" or "one or more inhibitors".
[0131] Any range given in absolute terms or in approximate terms is intended to cover both, and any definition used herein is intended to be clarifying and not restrictive. Although the numerical ranges and parameters describing the broad scope of the present invention are approximate, the numerical values described in the specific embodiments are reported as accurately as possible. However, any numerical value inherently contains certain errors caused by the standard deviation found in its corresponding experimental measurement. In addition, all ranges disclosed herein are understood to cover any and all subranges (including all fractional values and overall values) contained therein.
[0132] Any composition disclosed herein may comprise, consist of, or consist essentially of any element, component, and / or ingredient disclosed herein, or any combination of two or more of the elements, components, or ingredients disclosed herein.
[0133] Any method disclosed herein may comprise, consist of, or consist essentially of any method step disclosed herein or any combination of two or more of the method steps disclosed herein.
[0134] The transitional phrase "comprising," which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional unrecited elements, components, ingredients, and / or method steps.
[0135] The transitional phrase "consisting of" excludes any element, component, ingredient and / or method step not specified in the claim.
[0136] The transition phrase "consisting essentially of" limits the scope of a claim to the specified elements, components, ingredients and / or steps, and those that do not materially affect the basic and novel characteristics of the claimed invention.
[0137] As used herein, the term "about" means that the recited value is within the standard deviation found in their respective testing measurements, and if those errors are not determinable, "about" may mean, for example, within 5% of the recited value.
[0138] In addition, the present invention encompasses any and all possible combinations of some or all of the various aspects described herein. It should also be understood that the various changes and modifications made to the current preferred aspects described herein are obvious to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention and without reducing its expected advantages. Therefore, the appended claims are intended to cover such changes and modifications.
Claims
1. A method for inhibiting monomer polymerization, the method comprising: adding the composition to a process stream in an extractive distillation process, wherein the composition comprises a first inhibitor compound comprising a stable nitroxide radical; and a second inhibitor compound, the second inhibitor compound comprising phenylenediamine, wherein the process stream comprises micelles.
2. The method of claim 1, wherein the first inhibitor compound has formula (I): Where R1 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
3. The method according to claim 1 or claim 2, wherein the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-ol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-pentyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-hexyloxy 4-Heptyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Octyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Nonyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Decyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Undecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Dodecyloxy-2,2,6,6-tetramethylpiperidin-1-oxy; 4-Tridecyloxy-2,2, 6,6-tetramethylpiperidin-1-oxyl; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-nonadecyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-decyloxy-2,2, 6,6-tetramethylpiperidin-1-oxyl; 4-eicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-heneicosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-oxyl; 2,2,6,6-tetramethyl-4-(naphthalene-2-yloxy)piperidin-1-oxyl; and any combination thereof.
4. The method of claim 1, wherein the first inhibitor is a compound of formula III: wherein R3 is -O· or -OH; and R4 is C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
5. The method of claim 4, wherein the first inhibitor is selected from the group consisting of: 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl propionate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 2,6,6-tetramethylpiperidin-4-yl ester; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl dibenzoate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl palmitate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl behenate; 1-oxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate; and any combination thereof.
6. The method according to any one of claims 1 to 5, wherein the second inhibitor compound is a phenylenediamine of formula (IV) or formula (V): Where X1 and X2 are independently C1-C 22 Alkyl or aryl, wherein the alkyl and aryl groups are optionally substituted by one or more C1-C 22 Alkyl or aryl substituted.
7. The method according to any one of claims 1 to 6, wherein the second inhibitor is selected from the group consisting of: 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-dimethyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-diacetyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, N,N′-diphenyl-1,4-phenylenediamine, and any combination thereof.
8. The method of any one of claims 1 to 7, wherein the first inhibitor compound is present in the composition at a concentration of about 0.01 wt% to about 80 wt%.
9. The method of any one of claims 1 to 8, wherein the second inhibitor compound is present in the composition at a concentration of about 0.01 wt% to about 50 wt%.
10. The method of any one of claims 1 to 9, wherein the molar ratio of the first inhibitor compound to the second inhibitor compound is from about 100:1 to about 1:
100.
11. The method according to any one of claims 1 to 10, wherein the composition further comprises an organic solvent.
12. The process according to any one of claims 1 to 11, wherein the process stream further comprises an ethylenically unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, and any combination thereof.
13. The process of claim 12, wherein the process stream further comprises at least one polar extractive distillation solvent and at least one non-polar extractive distillation solvent in which the ethylenically unsaturated monomer is present.
14. The process of claim 13, wherein the at least one polar extractive distillation solvent in which the ethylenically unsaturated monomer is present and the at least one non-polar extractive distillation solvent are immiscible with each other.
15. The method of claim 13, wherein the ethylenically unsaturated monomer partitions to a greater extent into one of the at least one non-polar extractive distillation solvents than into the at least one polar extractive distillation solvent.
16. The method of claim 15, wherein the first inhibitor or the second inhibitor partitions to a greater extent into the at least one non-polar extractive distillation solvent than into the at least one polar extractive distillation solvent.
17. The process according to any one of claims 13 to 16, wherein the at least one non-polar extractive distillation solvent is selected from the group consisting of furfural, vinyl acetate, acrylonitrile, 1,3-butadiene, styrene, isoprene, cyclopentadiene, dicyclopentadiene, acrylic acid, methacrylic acid, tetrahydrofuran, pentane, hexane, heptane, octane, nonane, decane, undecane, dodecane, tridecane, tetradecane, benzene, toluene, ethylbenzene, ethyltoluene, methylene chloride, tetrachloromethane, pentene, hexene, heptene, octene, nonene, decene, undecene, dodecene, Tridecene, tetradecene, cyclopentane, cyclopentene, cyclohexane, cyclohexene, dicyclopentane, cyclopentadiene, dicyclopentadiene, ethyl acetate, ethyl propionate, ethyl butyrate, ethyl valerate, ethyl hexanoate, ethyl heptanoate, ethyl nonanoate, ethyl decanoate, ethyl undecanoate, ethyl dodecanoate, ethyl tridecanoate, ethyl tetradecanoate, ethyl pentadecanoate, ethyl hexadecanoate, ethyl octadecanoate, ethyl behenate, methyl acetate, methyl propionate, methyl butyrate, methyl valerate, methyl hexanoate, methyl heptanoate, methyl nonanoate, methyl decanoate, methyl undecanoate, methyl dodecanoate, methyl tridecanoate, methyl tetradecanoate , methyl pentadecanoate, methyl hexadecanoate, methyl octadecanoate, methyl behenate, propyl acetate, propyl propionate, propyl butyrate, propyl valerate, propyl hexanoate, propyl heptanoate, propyl nonanoate, propyl decanoate, propyl undecanoate, propyl dodecanoate, propyl tridecanoate, propyl tetradecanoate, propyl pentadecanoate, propyl hexadecanoate, propyl octadecanoate, propyl behenate, butyl acetate, butyl propionate, butyl butyrate, butyl valerate, butyl hexanoate, butyl heptanoate, butyl nonanoate, butyl decanoate, butyl undecanoate, butyl dodecanoate, butyl tridecanoate, butyl tetradecanoate, butyl pentadecanoate, butyl hexadecanoate, butyl octadecanoate Ester, butyl behenate, hexyl acetate, hexyl propionate, hexyl butyrate, hexyl valerate, hexyl caproate, hexyl heptanoate, hexyl nonanoate, hexyl decanoate, hexyl undecanoate, hexyl laurate, hexyl tridecanoate, hexyl tetradecanoate, hexyl pentadecanoate, hexyl hexadecanoate, hexyl octadecanoate, hexyl behenate, octyl acetate, octyl propionate, octyl butyrate, octyl valerate, octyl caproate, octyl heptanoate, octyl nonanoate, octyl decanoate, octyl undecanoate, octyl laurate, octyl tridecanoate, octyl tetradecanoate, octyl pentadecanoate, octyl hexadecanoate, octyl octadecanoate, octyl behenate, and any combination thereof.
18. The process according to any one of claims 13 to 17, wherein the at least one polar extractive distillation solvent is selected from N,N-dimethylformamide, furfural, N-methylpyrrolidone, acetonitrile, water and combinations thereof.
19. The method of any one of claims 1 to 18, wherein the composition is added to the process stream such that the concentration of the first inhibitor compound is from about 0.1 ppm to about 10,000 ppm.
20. The method of any one of claims 1 to 19, wherein the composition is added to the process stream such that the concentration of the second inhibitor compound is from about 0.1 ppm to about 10,000 ppm.
